NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗瘧疾藥的全球市場:2021年∼2025年

Global Anti-malarial Medicines Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 1008925
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
抗瘧疾藥的全球市場:2021年∼2025年 Global Anti-malarial Medicines Market 2021-2025
出版日期: 2021年05月07日內容資訊: 英文 120 Pages
簡介

全球抗瘧疾藥的市場規模在2021年∼2025年間,預測將成長到2億8752萬美元,在預測期間中預計將以5%的年複合成長率增長。

該市場成長的主要因素有為了撲滅瘧疾的強力財政支援。

本報告涵括抗瘧疾藥的全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

  • 摘要整理
  • 市場概要
  • 市場形勢
    • 市場生態系統
    • 價值鏈分析
  • 市場規模
    • 市場定義
    • 市場區隔分析
    • 2020年的市場規模
    • 市場預測:2020∼2025年預測
  • 波特的五力分析
    • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭的威脅
    • 市場情況

    市場區隔:各產品

    • 市場區隔
    • 各產品比較
    • 青蒿素化合物:市場規模與預測(2020年∼2025年)
    • 喹啉及相關化合物:市場規模與預測(2020年∼2025年)
    • 其他化合物:市場規模與預測(2020年∼2025年)
    • 各產品的市場機會
  • 客戶形勢
  • 各地區形勢
    • 各地區市場區隔
    • 各地區比較
    • 亞洲:市場規模與預測(2020年∼2025年)
    • 其他地區:市場規模與預測(2020年∼2025年)
    • 歐洲:市場規模與預測(2020年∼2025年)
    • 北美:市場規模與預測(2020年∼2025年)
    • 主要國家
    • 地區的市場機會
    • 市場推動因素
    • 市場課題
    • 市場趨勢
  • 業者情勢
    • 業者情勢
    • 創造性破壞狀況
  • 供應商分析
    • 交易廠商
    • 供應商的市場定位
    • AstraZeneca Plc
    • Bayer AG
    • Cipla Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
  • 附錄
    • 調查範圍
    • 美金的貨幣換算比率
    • 調查手法
    • 簡稱一覽
目錄
Product Code: IRTNTR43201

Technavio has been monitoring the anti-malarial medicines market and it is poised to grow by $ 287.52 million during 2021-2025, progressing at a CAGR of almost 5% during the forecast period. Our report on the anti-malarial medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by strong funding to eradicate malaria. In addition, strong funding to eradicate malaria is anticipated to boost the growth of the market as well.

The anti-malarial medicines market analysis includes the product segment and geographic landscape.

Technavio's anti-malarial medicines market is segmented as below:

By Product

  • Artemisinin compounds
  • Quinolines and related compounds
  • Other compounds

By Geography

  • Asia
  • ROW
  • Europe
  • North America

This study identifies the robust pipeline and recent drug approvals as one of the prime reasons driving the anti-malarial medicines market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anti-malarial medicines market covers the following areas:

  • Anti-malarial medicines market sizing
  • Anti-malarial medicines market forecast
  • Anti-malarial medicines market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-malarial medicines market vendors that include AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi SA, and Sun Pharmaceutical Industries Ltd. Also, the anti-malarial medicines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
  • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Product
    • Market segments
    • Comparison by Product
    • Artemisinin compounds - Market size and forecast 2020-2025
    • Quinolines and related compounds - Market size and forecast 2020-2025
    • Other compounds - Market size and forecast 2020-2025
    • Market opportunity by Product
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • North America - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • AstraZeneca Plc
    • Bayer AG
    • Cipla Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: Artemisinin compounds - Market size and forecast 2020-2025 ($ million)
  • 24: Artemisinin compounds - Year-over-year growth 2020-2025 (%)
  • 25: Quinolines and related compounds - Market size and forecast 2020-2025 ($ million)
  • 26: Quinolines and related compounds - Year-over-year growth 2020-2025 (%)
  • 27: Other compounds - Market size and forecast 2020-2025 ($ million)
  • 28: Other compounds - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Product
  • 30: Customer landscape
  • 31: Market share by geography 2020-2025 (%)
  • 32: Geographic comparison
  • 33: Asia - Market size and forecast 2020-2025 ($ million)
  • 34: Asia - Year-over-year growth 2020-2025 (%)
  • 35: ROW - Market size and forecast 2020-2025 ($ million)
  • 36: ROW - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ million)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: North America - Market size and forecast 2020-2025 ($ million)
  • 40: North America - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Product and service
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: Bayer AG - Overview
  • 55: Bayer AG - Business segments
  • 56: Bayer AG - Key offerings
  • 57: Bayer AG - Key customers
  • 58: Bayer AG - Segment focus
  • 59: Cipla Inc. - Overview
  • 60: Cipla Inc. - Business segments
  • 61: Cipla Inc. - Key offerings
  • 62: Cipla Inc. - Key customers
  • 63: Cipla Inc. - Segment focus
  • 64: F. Hoffmann-La Roche Ltd. - Overview
  • 65: F. Hoffmann-La Roche Ltd. - Business segments
  • 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • 67: F. Hoffmann-La Roche Ltd. - Key customers
  • 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • 69: GlaxoSmithKline Plc - Overview
  • 70: GlaxoSmithKline Plc - Business segments
  • 71: GlaxoSmithKline Plc - Key offerings
  • 72: GlaxoSmithKline Plc - Key customers
  • 73: GlaxoSmithKline Plc - Segment focus
  • 74: Mylan NV - Overview
  • 75: Mylan NV - Business segments
  • 76: Mylan NV - Key offerings
  • 77: Mylan NV - Key customers
  • 78: Mylan NV - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Sanofi SA - Overview
  • 90: Sanofi SA - Business segments
  • 91: Sanofi SA - Key offerings
  • 92: Sanofi SA - Key customers
  • 93: Sanofi SA - Segment focus
  • 94: Sun Pharmaceutical Industries Ltd. - Overview
  • 95: Sun Pharmaceutical Industries Ltd. - Business segments
  • 96: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 97: Sun Pharmaceutical Industries Ltd. - Key customers
  • 98: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations